Nilgün ÇINAR, Alper KARAOĞLAN, Ahmet MİDİ, Mehmet Alpay ÇAL, Bilal KETEN, Miraç Ayşen ÇAKMAK, Sevki ŞAHİN

Neuroprotective effect of ziprasidone: Preliminary results compared to haloperidol

Typical and atypical antipsychotic drugs are widely used to treat psychosis. The resent study investigated whether ziprasidone, an atypical antipsychotic drug, has a neuroprotective effect on hippocampal neurons in rats with experimentallyinduced transient cerebral ischemia comparatively with haloperidol which is a typical antipsychotic. Transient cerebral ischemia was induced by 10-minute occlusion of bilateral carotis communis arteries. The rats were divided into four groups: Shamoperated control group (Group I), ischemia control group (Group II), haloperidol-treated group (Group III) and ziprasidone-treated group (Group IV). Following 10-minute ischemia, Group III received 1mg/kg haloperidol intramuscularly and Group IV received 2.5 mg/kg ziprasidone intraperitoneally. The animals were sacrificed on the seventh day following induced ischemia to determine the number of intact neurons at hippocampus and dentate gyrus to demonstrate the effects of ischemia and efficacy of the treatments administered. Surviving cell numbers were found in the sham operated group; 198, in the ischemia control group; 80, in the haloperidol-treated group; 185, in ziprasidonetreated group; 189. The groups showed significant difference in the comparison of the surviving cell numbers. However, the number of surviving cells did not significantly different between the ziprasidone and haloperidol-treated group. Previous studies with the ischemia model have demonstrated protective effects of haloperidol on hippocampal region. The findings of the present study show that ziprasidone, which is an atypical antipsychotic drug, may produce neuroprotective effects as potent as haloperidol, which is a typical antipsychotic drug.

Keywords:

Brain ischemia, Haloperidol, Hippocampus, Neuroprotective agents, Ziprasidone,

PDF

___

Arango, C., Kirkpatrick, B., Koenig, J., 2001. At issue: Stress, hippocampal neuronal turnover, and neuropsychiatric disorders. Schizophr. Bull. 27, 477-480.
Bai, O., Zhang, H., Li, X.M., 2004. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain. Res. 1010, 81-86.
DeLeon, A., Patel, N.C., Crismon, M.L., 2004. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26, 649-666.
Duman, R.S., 2004. Depression: A case of neuronal life and death? Biol. Psychiatry. 56, 140-145.
Dunn, R.T., Frye, M.S., Kimbrell, T.A., Denicoff, K.D., Leverich, G.S., Post, R.M., 1998. The efficacy and use of anticonvulsants in mood disorders. Clin. Neuropharmacol. 21, 215-235.
Globus, M.Y.T., Busto, R., Dietrich, W.D., Martinez, E., Valdes, I., Gingsberg, M.D., 1988. Effect of ischemia on in vivo release of striatal dopamine, glutamate and gamma aminobutyric acid studies by intracerebral microdialysis. J. Neurochem. 51, 1455–1464. Harkany, T., Mulder, J., Horvath, K.M., Keijser, J., van der Meeberg, E.K., Nyakas, C., Luiten, P.G., 2001. Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (BAYx3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience. 108, 629-642.
Hashimoto, N., Matsumumoto, T., Mabe, H., Hashitaní, T., Nishino, H., 1994. Dopamine has inhibitory and accelerating effects on ischemia induced neuronal cell damage in the striatum. Brain. Res. Bull. 33, 281-288.
Iwasaki, Y., Ito, S., Suzuki, M., Nagahori, T., Yamamoto, T., Konno, H., 1989. Forebrain ischemia induced by temporary bilateral common carotid occlusion in normotensive rats. J. Neurol. Sci. 90, 155-165.
Johannessen, C.U., 2000. Mechanisms of action of valproate: A commendatory. Neurochem. Int. 37, 103-110.
Madhavan, L., Freed, W.J., Anantharam, V., Kanthasamy, A.G., 2003. 5-Hydroxytryptamine 1A receptor activation protects against N-Methyl-daspartate-induced apoptotic cell death in striatal and mesencephalic cultures. J. Pharmacol. Exp. Ther. 304, 913-923.
Matsuyama, S., Nei, K., Tanaka, C., 1997. Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain. Res. 761, 105-112.
Maurice, T., Su, T.P., 2009. The pharmacology of sigma-1 receptors. Pharmacol. Ther. 124, 195-206.
Meldrum, B., 1989. Excitotoxicity in ischemia. An overview. In: M.D. Ginsberg and W.D. Dietrich, Editors. Cerebrovascular Diseases. Sixteenth Research (Princeton) Conference Raven Press, New York. p.p. 47–60.
Nakata, N., Suda, H., Izumi, J., Tanaka, Y., Ikeda, Y., Kato, H., Itoyama, Y., Kogure, K., 1997. Role of hippocampal serotonergic neurons in ischemic neuronal death. Behav. Brain. Res. 83, 217-220.
Nemeroff, C.B., Lieberman, J.A., Weiden, P.J., Weiden, P.J., Harvey, P.D., Newcomer, J.W., Schatzberg, A.F., Kilts, C.D., Daniel, D.G., 2005. From clinical research to clinical practice: A 4-year review of ziprasidone. CNS. Spectr. 10, 1-20.
Ozdemir, H.H., Demir, C.F., Berilgen, M.S., Akgun, B., Kuloğlu, T., Kapan, O., Ilhan, S., Balduz, M., 2013. Protective effects of memantine in experimentally induced cerebral ischemia and reperfusion injury in rats. Türk. Nörol. Derg. 19, 85-89.
Park, S.W., Lee, S.K., Kim, J.M., Yoon, J.S., Kim, Y.H., 2006. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci. Lett. 402, 25-29.
Park, S.W., Lee, C.H., Lee, J.G., Lee, S.J., Kim, N.R., Choi, S.M., Kim, Y.H., 2009. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. J. Psychiatr. Res. 43, 274-281. doi: 1016/j.jpsychires.2008.05.010.
Prehn, J.H.M., Welsch, M., Backhauss, C., Nuglisch, J., Ausmeier, F., Karkoutly, C., Krieglstein, J., 1993. Effects of serotonergic drugs in experimental brain ischemia: Evidence for a protective role of serotonin in cerebral ischemia. Brain Research. 630, 10-20. Raymond, J.R., Mukhin, Y.V., Gelasco, A., Nuglisch, J., Ausmeier, F., Karkoutly, C., Krieglstein, J., 2001. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 92, 179-212.
Richards, D.A., Orenovich, T.P., Symon, L., Curzon, G., 1993. Extracellular dopamine and seratonin in the rat striatum during transient ischemia of different severities: A microdialysis study. J. Neurochem. 60, 128-136.
Roh, K., Roh, S., Yang, B.H., Lee, J.S., Chai, Y.G., Choi, M.R., Park, Y.C., Kim, D.J., Kim, D., Choi, J., Kim, S.H., 2008. Effects of haloperidol and risperidone on the expression of heat shock protein 70 in MK-801-treated rat C6 glioma cells. Prog. Neuropsychopharmacol Biol. Psychiatry. 32, 1793-1797. doi: 10.1016/j.pnpbp.2008.07.018.
Schetz, J.A., Perez, E., Liu, R., Chen, S., Lee, I., Simpkins, J.W., 2007. A prototypical Sigma-1 receptor antagonist protects against brain ischemia. Brain. Res. 1181, 1-9.
Schmidt, A.W., Lebel, L.A., Howard, H.R. Jr, Zorn, S.H., 2001. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425, 197-201.
Shapiro, D.A., Renock, S., Arrington, E., 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 28, 1400-1411.
Strosznajder, J., Chalimoniuk, M., Samochocki, M., 1996. Activation of serotonergic 5-HT1A receptor reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus. Neurochem. Int. 28, 439-444.
Yulug, B., Yildiz, A., Guzel, O., Kilic, E., Schäbitz, W.R., Kilic, E., 2006a. Risperidone attenuates brain damage after focal cerebral ischemia in vivo. Brain. Res. Bull. 69, 656-659.
Yulug, B., Yildiz, A., Hudaoglu, O., Kilic, E., Cam, E., Schäbitz, W.R., 2006b. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain. Res. Bull. 71, 296-300.